These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 23327199)

  • 21. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis.
    Wang FY; Fang B; Qiang XH; Yu TO; Zhong JR; Cao J; Zhou LX
    Biomed Res Int; 2016; 2016():9508493. PubMed ID: 27340674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
    Mao L
    Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin].
    ; Lin HY
    Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(7):451-7. PubMed ID: 17459221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis.
    Wu JF; Ma J; Chen J; Ou-Yang B; Chen MY; Li LF; Liu YJ; Lin AH; Guan XD
    Crit Care; 2011; 15(5):R220. PubMed ID: 21933399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.
    Li Yumin ; Chen Hao ; Li Xun ; Zhou Wence ; He Minyan ; Chiriva-Internati M; Wachtel MS; Frezza EE
    J Intensive Care Med; 2009; 24(1):47-53. PubMed ID: 19033321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A
    Huang X; Mao W; Hu X; Qin F; Zhao H; Zhang A; Wang X; Stoppe C; Zhou D; Ke L; Ni H;
    Gut Liver; 2024 Sep; 18(5):906-914. PubMed ID: 38356344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
    Peng D; Xing HY; Li C; Wang XF; Hou M; Li B; Chen JH
    BMC Gastroenterol; 2020 Oct; 20(1):348. PubMed ID: 33076834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
    Li X; Liu L; Yang Y; Yang X; Wang C; Li Y; Ge Y; Shi Y; Lv P; Zhou H; Luo P; Huang S
    Int Immunopharmacol; 2021 Jan; 90():107022. PubMed ID: 33160854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients].
    Su L; Meng FS; Tang YQ; Wen Q; Liu YS; Tang LQ; Duan PK; Luo RJ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Mar; 21(3):147-50. PubMed ID: 19278583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymalfasin for the treatment of chronic hepatitis B.
    Chien RN; Liaw YF
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):9-16. PubMed ID: 15482167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.
    Pontes-Arruda A; Martins LF; de Lima SM; Isola AM; Toledo D; Rezende E; Maia M; Magnan GB;
    Crit Care; 2011 Jun; 15(3):R144. PubMed ID: 21658240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
    Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
    Front Immunol; 2021; 12():568789. PubMed ID: 34149679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy improves immune homeostasis and increases survival rate of septic patients.
    Huang SW; Chen J; Ouyang B; Yang CH; Chen MY; Guan XD
    Chin J Traumatol; 2009 Dec; 12(6):344-9. PubMed ID: 19930904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymosin alpha1. SciClone Pharmaceuticals.
    Billich A
    Curr Opin Investig Drugs; 2002 May; 3(5):698-707. PubMed ID: 12090542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting the Outcomes of Subjects With Severe Community-Acquired Pneumonia Using Monocyte Human Leukocyte Antigen-DR.
    Zhuang Y; Li W; Wang H; Peng H; Chen Y; Zhang X; Chen Y; Gao C
    Respir Care; 2015 Nov; 60(11):1635-42. PubMed ID: 26264418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.
    You J; Zhuang L; Tang BZ; Yang WB; Ding SY; Li W; Wu RX; Zhang HL; Zhang YM; Yan SM; Zhang L
    World J Gastroenterol; 2001 Jun; 7(3):411-4. PubMed ID: 11819801
    [No Abstract]   [Full Text] [Related]  

  • 38. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
    Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y
    Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
    Shehadeh F; Benitez G; Mylona EK; Tran QL; Tsikala-Vafea M; Atalla E; Kaczynski M; Mylonakis E
    J Infect Dis; 2023 Jan; 227(2):226-235. PubMed ID: 36056913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.
    Wu M; Ji JJ; Zhong L; Shao ZY; Xie QF; Liu ZY; Wang CL; Su L; Feng YW; Liu ZF; Yao YM
    Int Immunopharmacol; 2020 Nov; 88():106873. PubMed ID: 32795897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.